300 TECHNOLOGY SQUARE, CAMBRIDGE, MA
Investor Presentation
Annual Meeting Results: Election of Class II Directors - Sujay Kango, Anne Mc...
Highlights Recent Business Achievements and Reports Q1 2026 Financial Results
Annual Report to Security Holders
Other Events
Dianthus Therapeutics Enters Underwriting Agreement for $593.5M Offering
Material disclosure
Q1
FY 2025
Q3
Q2
FY 2024
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Additional Securities
Registration Statement for Securities to be Offered to Employees
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Definitive Proxy Statement
Additional Proxy Materials
Notice of Proposed Sale of Securities
Statement of Changes in Beneficial Ownership